Peptides DB
Research-centric peptide and protocol reference hub

P21 (P021) record · updated 21h ago

Neuro & moodGrade B · human evidenceResearch use only
All 14 studiesJump to the evidenceCompare
What is P21 (P021) used for?

P21 (P021) is a CNTF-derived neurogenic peptide researched preclinically for cognitive decline, tau pathology, and BDNF-mediated neuroprotection. Research-use only with no human trial data.

How it works: BDNF signaling modulation

Primarily researched for · Neuro & mood

Development stage

where P21 (P021) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 53 registered trials. It describes the research record, not a recommendation.

Identity
NameP21 (P021)
Chain length—
Molecular weight578.7 Da
FormulaC27H42N6O8
Structure typeNot established
ClassNeuro
Research levelPreclinical
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 56599151. No verified residue count for this compound.

Pharmacology
MechanismBDNF signaling modulation
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.70
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 24, 2026. How this works →
Research stats
Total studies14
Human / animal / cellular4 / 4 / 4
Highest trial phasePreclinical
Years covered2008–2026
Latest study2d ago
Publication history
20082026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

14 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Sex differences in senescence burden within human osteoarthritic synovial fibroblasts
FindingNot reported in abstract.
In vitro2026Full text read0.70
Novel senolytic and senescence-suppressing compounds overcome senescence-driven chemoresistance in NSCLC
Finding15 - 30% response rates to platinum-based regimens in advanced NSCLC.
In vitro2026Full text read0.70
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.
Finding59% of patients (26 of 44) showed treatment-emergent genomic alterations in the RAS signaling pathway.
Human2026Full text read0.80
Structure-based screening and identification of a novel Aurora-A-targeting peptide with antiproliferative activity against prostate cancer cells.
FindingKd = 0.72 ± 0.04 μM for Peptide-1 binding to Aurora-A.
In vitro2026Full text read0.70
Author Correction: p21-activated kinase 4 counteracts PKA-dependent lipolysis by phosphorylating FABP4 and HSL.
TakeawayNot reported in abstract.
—2026Title only0.10
Chemically induced skin tumors arise from long-lived stem cells of the upper hair follicle.
TakeawayNot reported in abstract.
Animal2026Title only0.10
Bleomycin as an Inducer of Senescence in RAW 264.7 Macrophages
Finding80% senescence-associated beta-galactosidase (SA-β-gal) positivity with bleomycin.
Animal2026Full text read0.80
Overexpression of LINC00472 alleviates diabetic kidney disease progression via the miR-21-5p/STAT3 axis.
FindingNot reported in abstract.
Human2026Full text read0.70
Discovery of a novel and potent KRAS<sup>G12V</sup>-targeting peptide with antiproliferative activity against colorectal cancer cells.
FindingNot reported in abstract.
In vitro2026Full text read0.70
Lysozyme revisited: evaluating models of a reference protein in structural biology.
FindingNot reported in abstract.
review2026Full text read0.70
Recombinant human collagen XVII protects epidermal stem cells from blue light-induced photoaging by downregulating the Notch pathway.
FindingNot reported in abstract.
Animal2026Full text read0.70
Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder.
FindingNot reported in abstract.
Animal2024Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching P21 (P021) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much P21 (P021) is discussed should be drawn from it.